BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19243586)

  • 1. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.
    Giorgi Rossi P; Ricciardi A; Cohet C; Palazzo F; Furnari G; Valle S; Largeron N; Federici A
    BMC Public Health; 2009 Feb; 9():71. PubMed ID: 19243586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
    Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
    Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain.
    Castellsagué X; Rémy V; Puig-Tintoré LM; de la Cuesta RS; Gonzalez-Rojas N; Cohet C
    J Low Genit Tract Dis; 2009 Jan; 13(1):38-45. PubMed ID: 19098605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
    Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
    Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of invasive cervical cancer and direct costs associated with its management in Italy.
    Ricciardi A; Largeron N; Giorgi Rossi P; Raffaele M; Cohet C; Federici A; Palazzo F
    Tumori; 2009; 95(2):146-52. PubMed ID: 19579858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap-smear in an opportunistic screening.
    Gram IT; Macaluso M; Stalsberg H
    Acta Obstet Gynecol Scand; 1998 Feb; 77(2):228-32. PubMed ID: 9512333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of screening and treatment of cervical dyskaryosis in Germany.
    Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
    Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
    Brown RE; Breugelmans JG; Theodoratou D; Bénard S
    Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.
    Salo H; Leino T; Kilpi T; Auranen K; Tiihonen P; Lehtinen M; Vänskä S; Linna M; Nieminen P
    Int J Cancer; 2013 Sep; 133(6):1459-69. PubMed ID: 23463194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
    Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
    Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Easy screening for everyone.
    Palazzi M; Severi M; Imolesi C; Vitali P; Farneti M; Bianchini A; Cristallo T
    Epidemiol Prev; 2016; 40(3-4):179-84. PubMed ID: 27436251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical cancer screening in immigrant women in Italy: a survey on participation, cytology and histology results.
    Campari C; Fedato C; Iossa A; Petrelli A; Zorzi M; Anghinoni E; Bietta C; Brachini A; Brezzi S; Cogo C; Giordano L; Giorgi D; Palazzi M; Petrella M; Schivardi MR; Visioli CB; Giorgi Rossi P;
    Eur J Cancer Prev; 2016 Jul; 25(4):321-8. PubMed ID: 26207563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.
    Perkins RB; Langrish SM; Stern LJ; Burgess JF; Simon CJ
    Womens Health Issues; 2010; 20(1):35-42. PubMed ID: 19944623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).
    Carozzi FM; Iossa A; Scalisi A; Sideri M; Andersson KL; Confortini M; Del Mistro A; Maina G; Ronco G; Raggi P; Schiboni ML; Zappa M; Giorgi Rossi P
    Epidemiol Prev; 2015; 39(3 Suppl 1):84-90. PubMed ID: 26405780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.